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In May 1993, a new hantaviral illness,
hantavirus pulmonary syndrome (HPS), was
recognized in the southwestern region of the United
States (1). HPS is a viral zoonosis characterized by
a febrile prodrome in young, healthy adults; the
disease progresses to respiratory failure with the
clinical picture of adult respiratory distress
syndrome (ARDS). The striking pulmonary
involvement differentiates HPS from a previ-
ously described hantaviral disease known as
hemorrhagic fever with renal syndrome.
In the first 100 HPS cases in the United
States, the average age was 34.9 years (range 11
to 69); eight cases were in children or adolescents
under 16 years of age (2). In Argentina, from 1987
to July 1997, 114 cases were diagnosed in three
areas of the country where several strains of new
world hantaviruses are known to cause HPS
diseases (3,4). Before 1995, no cases were
detected in Argentine children under 12 years of
age. Ten cases were reported among adolescents
(13 to 19 years) with a case-fatality rate of 30%
(Instituto Nacional de Enfermedades Virales
Humanas, [INEVH], unpub. data).
The initial case definition referred to ARDS
and included adults and young adults (5) as the
affected population. The lack of HPS cases among
children in the original outbreaks led to a
circulating hypothesis that children were not at
risk or were at a very low risk for HPS. Another
hypothesis was that children were protected from
pulmonary involvement, perhaps by immune
system immaturity or a lack of other risk factors
(such as cigarette smoking) for lung injury.
In this report we describe five cases in
children; in all of them the etiologic diagnosis was
established by the presence of immunoglobulin M
(IgM) antibody to Sin Nombre virus (SNV)
antigens. Serologic results for two of the children
were also positive for SNV IgG antibody. Serum
samples were tested for IgM and IgG antibodies
to SNV by enzyme-linked immunosorbent assay
(ELISA) (6). An ELISA titer greater than or equal
to 1:400 was considered positive (Table 1).
Patient 1 was identified during the study of the
first outbreak in southern Argentina in 1995 (5).
Four patients in this outbreak were from the same
family. During interviews of the family members,
we found that a 9-year-old boy had a febrile disease
without respiratory involvement, beginning on
April 19. Serology performed on May 3, 14 days
after the onset of symptoms, demonstrated IgM and
IgG antibodies to SNV antigens.
Hantavirus Infection in
Children in Argentina
Clinical hantavirus infection was diagnosed in five Argentine children ages 5 to 11
years by immunoglobulin M (IgM)-  capture enzyme-linked immunosorbent assay using
Sin Nombre virus (SNV) antigens. Death in three of the children was associated with
absence of detectable IgG to SNV antigens. An additional two cases in healthy children
were studied: one, a breast-fed 15-month-old whose mother died of suspected
hantavirus pulmonary syndrome (HPS) 8 months previously, had hantavirus
IgG (³ 1:6400); a second, whose mother survived HPS during month three of
pregnancy, apparently had maternal antibodies no longer detectable 1 year after birth.
Table 1. Hantavirus infection in children, Argentina, 1995–
1997
Serologya
Date
Age Date of IgM
Case Sex (yrs) onset IgG Areab Outcome
  1 M   9 4-19-95 5-3-95 South Alive
>6400
  1600
  2 F   5 3-21-97 3-23-97 North Dead
>6400
   Neg
  3 M   9 3-30-97 4-3-97 North Alive
 1600
   400
  4 F 11 4-14-97 4-16-97 North Dead
 1600
  Neg
  5 M   5 4-27-97 4-28-97 Central Dead
 1600
  Neg
aTiter expressed as the reciprocal of the serum dilution
reactive in enzyme-linked immunosorbent assay.
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The other four cases in children were
identified during routine surveillance. From
1995 to 1997, samples from 25 children (ages 3
months to 12 years; mean = 5.8 years) were sent
to INEVH for diagnosis. Table 2 summarizes
the main clinical and laboratory findings. None
of the children had renal failure; patient 2 had
uremia of 0.30 g/l, and patient 4 had a serum
creatinine level of 1.40 g/l. All patients who
later died received supplemental oxygen as
part of their treatment.
Two special situations involving children
arose during the study of the first cases of HPS in
El Bolsón in 1995. 1) A woman belonging to the
family of patient 1 contracted HPS during the
first quarter of pregnancy. She had a febrile
syndrome, without respiratory failure; chest X-
rays showed bilateral interstitial infiltrates.
Serologic tests showed both SNV IgM (³ 1:6400)
and IgG (³ 1:6400) on April 22, 1995, 8 days after
the onset of symptoms. She delivered a healthy
infant in October 1995. A sample of the newborn’s
cord blood was positive for SNV IgG (³ 1:6400)
and negative for SNV IgM. A serum sample
drawn from the mother at the same time had a
SNV IgG titer ³  1:6400 and was negative for SNV
IgM. A second serum sample, taken from the baby a
year later during November 1996, had no
detectable SNV IgG or IgM. 2) During a
retrospective search for cases fulfilling the HPS
case definition, a woman who died of ARDS in
September 1994 was considered to have a possible
case. No serum samples or autopsy tissues were
available to make an etiologic diagnosis. Before
dying, this woman breast-fed a 7-month-old baby;
when tested for antibodies 8 months later in May
1995 at 15 months of age, the baby had SNV IgG
(³ 1:6400) and no detectable SNV IgM antibodies.
A second serologic sample, collected 18 months
later in November 1996, still had SNV IgG
antibodies, with a similar titer. Both babies have
continued to develop normally as of October 1997.
A case similar to that of patient 1 was
detected in New Mexico in June 1993 (7) in the
course of the investigation of a fatal HPS case. In
this case, the patient also had a mild clinical
course that did not meet the surveillance case
definition for HPS. This case definition (revised
9/96) is as follows: “a febrile illness characterized
by bilateral diffuse interstitial edema that may
radiographically resemble ARDS, with respira-
tory compromise requiring supplemental oxygen,
developing within 72 hours of hospitalization,
and occurring in a previously healthy person; or
an unexplained respiratory illness resulting in
death, with an autopsy examination demon-
strating noncardiogenic pulmonary edema
without an identifiable cause” (8).
Our remaining four cases were sporadic, in
persons without previous contact with other HPS
patients, and were suspected because their
clinical symptoms were typical of HPS. Results of
serologic testing with SNV antigens of the
household contacts in cases 2 and 5 (five persons
Table 2. Laboratory results and clinical features of children with hantavirus infection, Argentina, 1995–1997
Tests and Case
features 1 2 3 4 5
Leukocytes 9,200   27,000   12,800 10,600 69,200
  (/mm3)
Hematocrit (%)      44          66          43        55        53
Thrombocytes    NDa 266,000 200,000 97,000      ND
  (/mm3)
Sedimentation rate    ND            4          28          8          1
  (mm/hr)
GOT/GPTb   ND Increased Increased Increased Increased (mild)
Chest X-ray    HIc      DIId         DII       DII      DII
Respiratory None Distress Slight dyspnea Tachypnea, Acute respiratory
  symptoms clinical and insufficiency
X-ray
disassociation,
hypoventilation
aND: Not done.
bGOT/GPT: Glutamic oxalacetic transaminase/Glutamic pyruvic transaminase.
cHI: Hilar indistinctness.
dDII: Diffuse interstitial infiltrate.87 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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each) were negative. The clinical, radiologic, and
laboratory findings were similar in children and
in adults; severely ill patients had greater
variation in laboratory values than mild cases,
and in fatal cases, only SNV IgM was present.
The case-fatality rate in this series was
60%, but the small number of cases does not
permit conclusions. In previously reported
cases in adolescents 13 to 19 years of age, the
case-fatality rate was 30%.
These cases originated in the three areas
where the illness is endemic in Argentina. This is
an important point because an unusual case of
HPS in southern Argentina, with the possibility
of person-to-person transmission, had been
reported (9,10). Patient 1 and the baby that was
breast-feeding when the mother died of suspected
HPS could be further instances of person-to-
person transmission.
A case of hemorrhagic fever with renal
syndrome and pregnancy was reported in 1992
(11); the dynamics of serum antibody persistence
were similar to those found in the one instance
where we believe antibody was passively
transferred from mother to baby. These results
indicate that HPS should be considered in the
differential diagnosis of respiratory distress or
atypical bilateral pneumonia in children, at least
in areas where these diseases have been
confirmed. Mild disease should be considered too,
especially in contacts of HPS patients and in
younger age groups.
Our findings also suggest the transfer of
passive antibodies from mother to fetus (without
fetal infection) and the possibility of transmission
of infection by maternal breast feeding.
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Cuba had its first dengue epidemic of modern
times in 1977; transmission continued probably
until 1981, and more than 500,000 mild cases were
reported. A 1978 serologic survey for flavivirus
antibody indicated that 44.6% of the Cuban
population had been infected with dengue-1 virus,
whereas before 1977 only 2.6% had antibodies (1,2).
A second dengue epidemic in 1981, caused by
dengue-2 virus (2), was unusually severe and
widespread. Of 344,203 cases, 10,312 were
clinically classified as dengue hemorrhagic fever/
dengue shock syndrome (DHF/DSS), and 158
persons (101 children and 57 adults) died (3).
Before 1981, only 60 suspected or confirmed DHF
sporadic cases had been reported in the region
(4). Dengue-2 virus isolated during the 1981
epidemic was classified in the same genotype as
New Guinea 1944 (5). Not previously known to
circulate in the Americas, this genotype was not
isolated again in the region until 1994 in
Venezuela and in 1995 in Mexico (6). Retrospec-
tive studies show that although the 1981
epidemic was detected in May, the first cases
occurred in December 1980. After the epidemic
ended on October 10, 1981, a campaign to
improve mosquito control and eradicate Aedes
aegypti was immediately launched. Eradication
was not achieved, but most of the 169 Cuban
municipalities were free of the vector.
Passive Surveillance—1981
A passive dengue surveillance system was
established at the end of the 1981 epidemic. Of
9,543 paired sera (acute- and convalescent-
phase) from all suspected dengue patients, only
14 showed seroconversion to immunoglobulin G
(IgG) by enzyme-linked immunosorbent assay
(ELISA) (7); none developed IgM antibodies to
dengue virus by capture IgM ELISA (8). Dengue
virus infection was excluded on the basis of
clinical and epidemiologic investigation. No Ae.
aegypti mosquitoes were found in the residence
localities of these patients. The surveillance
system detected cases, imported from other Latin
American countries, that had no evidence of
indigenous transmission. Since 1987, 4,983
samples received through the surveillance system
for measles and rubella, as well as paired sera of
patients with rash, were studied for dengue
antibodies [María Guzmán, World Health Organi-
zation (WHO)/Pan American Health Organization
(PAHO) Collaborating Center for the Study of Viral
Diseases, unpub. info.]. No dengue cases were
identified. The low Ae. aegypti premise indexes and
the results of the passive surveillance system
indicate no dengue transmission in Cuba between
1981 and the end of 1996. However, reinfestation
has occurred in some areas; the municipality of
Santiago de Cuba was reinfested in 1992 by
Ae. aegypti transported in imported tires (9).
Active Surveillance—1997
In January 1997, the Institute of Tropical
Medicine “Pedro Kourí” of the Cuban Ministry of
Health (a WHO/PAHO Collaborating Center for
the Study of Viral Diseases) established an active
surveillance system for dengue in Santiago de
Cuba municipality. The municipality is located in
Santiago de Cuba province, in the eastern part of
the country, and has several risk factors for the
reemergence of dengue: limited water supply,
inadequate eradication efforts, high vector
infestation, and increasing migration of people
from Latin American and Caribbean disease-
endemic countries to the municipality. Following
the Guidelines for the Prevention and Control of
Dengue and Dengue Hemorrhagic Fever in the
Americas (4), this surveillance system actively
Reemergence of Dengue in Cuba: A 1997
Epidemic in Santiago de Cuba
After 15 years of absence, dengue reemerged in the municipality of Santiago
de Cuba because of increasing migration to the area by people from disease-
endemic regions, a high level of vector infestation, and the breakdown of
eradication measures. The 1997 epidemic was detected early through an active
surveillance system. Of 2,946 laboratory-confirmed cases, 205 were dengue
hemorrhagic fever, and 12 were fatal. No deaths were reported in persons under 16
years of age. Now the epidemic is fully controlled.90 Emerging Infectious Diseases Vol. 4, No. 1, January–March 1998
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searched for febrile patients in the primary
health-care subsystem whose clinical picture was
compatible with dengue fever and whose sera
collected 5 to 6 days after onset of the disease
contained dengue IgM antibodies. As a result of
this system, dengue cases were detected on
January 28, 1997, in one area of the municipality.
In three of the first seven cases, dengue-2 virus
was detected by polymerase chain reaction (10)
and was confirmed by viral isolation and
identification using C6/36 cell line and mono-
clonal antibodies to the four dengue serotypes.
Although retrospective seroepidemiologic
studies indicated that the initial transmission
occurred during the second half of December
1996, it is highly probable that the cases detected
on January 28 were the first. Of 60,000 cases
reported from the emergency rooms of Santiago
de Cuba hospitals from November 1 to January
28, 592 were clinically compatible with dengue
fever. Home interviews of these 592 patients
reduced the figure to 154. Blood samples from 143
of 154 patients were examined for IgM
antibodies, but no positive cases were detected.
The breakdown of the vector control
campaign in this municipality interfered with our
efforts to abort the epidemic, despite the early
detection of the first dengue cases; however, the
partial vector control measures implemented
once the outbreak was detected prevented its
extension to the other 30 Cuban municipalities
infested with the Ae. aegypti mosquito.
     Active surveillance continued from January to
July 1997. Serologic confirmation of cases was
carried out by IgM capture ELISA, confirming
recent infection. The serologic diagnosis was
decentralized to the Provincial Laboratory in
Santiago de Cuba, which used an ultramicro-
ELISA for dengue IgM detection (11). The Institute
of Tropical Medicine served as the national
reference laboratory for serology, viral isolation,
and strain identification and characterization.
During the epidemic, 17,114 febrile patients
were initially  considered to have dengue, but serologic
testing of 10,024 of these patients confirmed dengue
in only 2,946; 46 dengue-2 isolates from 160 serum
samples were obtained. The nucleotide sequence of
the E\NS1 gene junction of the first isolated strain
(12) indicated that it belonged to the Jamaica
genotype, which during recent years is being
transmitted extensively throughout Latin Ameri-
can and Caribbean countries and is associated with
DHF/DSS in some countries (6,13).
Epidemiology
After the end of the 1981 Cuban DHF
epidemic, seroepidemiologic studies in Palmira,
Cienfuegos, and Cerro municipalities examined
dengue-1 and dengue-2 seroprevalence in these
populations (14,15). Taking into consideration
these data and the total population of the
Santiago de Cuba municipality, we estimated the
prevalence of dengue-1 and dengue-2 antibodies.
The estimated total population at risk for
dengue-2 infection was 301,986 adults and
children susceptible to a primary infection by any
dengue virus serotype (63.5% of the population)
and 88,108 adults with antibodies to dengue-1
virus acquired during the  epidemic of 1977 to
1980, now susceptible to a secondary infection
with dengue-2 and at increased risk for DHF/DSS
(18.5% of the population).
The earlier Cuban experience (3) confirms
other reports of secondary infection (dengue-1 and
dengue-2) as the main risk factor for DHF/DSS.
During the 1997 dengue outbreak, secondary
infection was again confirmed as a risk factor for
DHF/DSS. Of the 2,946 confirmed cases, 205
(including 12 fatal adult cases) were classified as
DHF/DSS cases according to the criteria estab-
lished by PAHO (4). DHF/DSS was observed mostly
in adults, the only age group in whom secondary
infection was possible. DHF/DSS-compatible symp-
toms were seen only in one child with primary
infection. Preliminary studies indicated that
secondary infection was present in 100 (98%) of 102
DHF/DSS cases. In fatal cases, secondary infection
could be documented in 11 (92%) of 12 cases. In
Thailand the greatest risk appeared when the
secondary infection occurred 6 months to 5 years
after the primary one (16). For that reason, an
epidemic of DHF/DSS was not expected in
Santiago de Cuba, perhaps only sporadic cases.
However, DHF/DSS in adults who contracted a
secondary infection at least 16 years after the
primary infection was not previously reported.
Because in Cuba dengue-1 circulated from
1977 to 1980-81, the youngest patients expected
to contract secondary infection should be older
than 16 years of age; the youngest DHF/DSS
patient with confirmed secondary infection was a
17-year-old, which indicates that the “enhancing”
antibodies can circulate and be effective for at
least 16 years and maybe for life.
A significant number of febrile patients with
suspected dengue had respiratory signs and
symptoms; therefore, simultaneous circulation of91 Vol. 4, No. 1, January–March 1998 Emerging Infectious Diseases
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respiratory or other pathogens was considered.
Serologic screening for respiratory viruses using
hemagglutination-inhibition and ELISA con-
firmed that 29.3% of 41 nonconfirmed dengue
cases were influenza A, influenza B, or
adenovirus infections. Additionally, some chil-
dren had fever and rash clinically compatible
with herpangina, and some had diarrheal disease
with fever, as is common in Cuba during the
summer. These febrile syndromes contributed to
the high number of patients whose infections
were provisionally considered suspect dengue
cases. Suspect dengue cases were broadly defined
to maximize sensitivity of detection and retain all
possible dengue cases. This active surveillance
excluded other febrile syndromes but recorded
them as suspected cases. In practice, the risk
perception by the population was very high,
especially when the epidemic was officially declared
and deaths were noted. Both the patients and the
health providers appeared to think of dengue as
the first diagnostic possibility. For this reason,
the figure of 17,114 cases was considered the
magnitude of the epidemic from the clinical
management perspective. Since most cases were
tested serologically, the incidence of clinical cases
was probably close to the 2,946 serologically or
virologically confirmed cases. Because asymp-
tomatic and subclinical dengue cases are frequent,
especially in children, the true rate of infection
may be higher. In a separate and limited study on
asymptomatic contacts of dengue cases, for every
clinical case, 13.9 asymptomatic or subclinical
cases were produced. Serologic studies of contacts
in Santiago de Cuba are planned for a more in-
depth study of this question.
Clinical Management
The health authorities established a liberal
policy of hospitalization that varied with the
availability of beds. Hospitalization permitted
vector control of the human reservoir, more
precise case classification, and close clinical
surveillance.
When beds were available, all patients with
suspected cases were hospitalized. When the
numbers of patients surpassed the availability of
beds, patients were treated at home under the
supervision of the family doctor. The family
doctor transferred the patient to the hospital if
any medical complication appeared. Wards with
specialized personnel were established where the
patients were protected from vectors, and
observation wards were organized for patients
with complications. Intensive and intermediate
care units, as well as an emergency subsystem for
the transfer of patients from one unit to another,
were available. As in 1981, some patients rapidly
developed hypovolemic shock and died within
hours of admission to the hospital (17).
An ad hoc task force followed the case
definitions for dengue and DHF/DSS established
by PAHO (4) for classifying the cases at the
closure of the medical record. The accumulated
experience of the Cuban scientists and doctors
and the increased international knowledge about
dengue and DHF/DSS in the last 15 years
permitted a much deeper and more comprehen-
sive study of this outbreak with more accurate
classification and management of cases than in
1981. Nevertheless, the case-fatality rate was
three times higher, mainly because of a much
better classification of DHF/DSS cases. Other
countries in the region with a very accurate case
classification, such as Puerto Rico (13), also have
a high case-fatality rate.
Vector Control
The campaign to control the vector started
before the beginning of the 1997 dengue outbreak
and is well established. Although the campaign
required the mobilization of scarce financial
resources and experts from all over the country,
early intervention prevented spread of the
outbreak to other potentially vulnerable mu-
nicipalities. Of 169 municipalities in Cuba, 30
had Ae. aegypti mosquitoes. The epidemic was
limited to the municipality of Santiago de Cuba;
no autochthonous transmission to other munici-
palities of the province or country was detected.
An active search for cases detected transmis-
sion very early, before “fever alert” signaled an
outbreak. In the Provincial Center for Hygiene,
Epidemiology, and Microbiology of Santiago de
Cuba, a special Unit for Analysis and Trends
maintains a permanent fever alert system. For
several years, this system has provided a weekly
tabulation of febrile patients for every popula-
tion. The tabulation allows us to evaluate fever
alert (4) as applied to an active surveillance
system. Because the fever alert did not appear in
the epidemic area until May 1997, after the
epidemic was already occurring, we consider
fever alert an indicator with low sensitivity for the
early and timely detection of dengue transmission,
at least under the conditions of this study.